allergens driven by antigen-presenting cells (APC), T lymphocytes and their secreted products such as cytokines and chemokines, and sustained by effector cells such as mast cells, basophils, and eosinophils (1) . The organs targeted by aeroallergen-induced inflammation are the lungs, the nose, and the eye, with their corresponding expressions in asthma, rhinitis and conjunctivitis. The only treatment able to modify the immune response underlying allergic inflammation is allergen specific immunotherapy (SIT) (2) . To properly evaluate the immunologic effects of SIT, an appraisal of the characteristics of the different cells and factors involved in allergic inflammation is needed.
Starting from APC, dendritic cells (DCs) are critical players in allergic airway inflammation and have a prominent role in presenting allergens to T cells and in inducing polarization towards Thl (associated to tolerance) orTh2 (associated to atopic response) cell types (3) . In the sublingual mucosa, these cells are sparsely distributed, including the external epithelial layer, and show morphological features of the Langerhans cells present in various areas of the body. They share with Langerhans cells the presence of Birbeck intracytoplasmatic granules but are characterized by the expression of the high affinity IgE receptor FcepsilonRI related in atopic subjects to serum IgE levels (4) . Engagement of dendritic cell IgE receptors with allergen molecules elicits the production of cytokines, such as IL-IO and TGF-beta, and up-regulates the synthesis of indoleamine 2,3-dioxygenase, an enzyme which metabolizes tryptophan, which is essential for T cell proliferation (5) .
Concerning T cells, it is well-known that allergic subjects have an imbalance between Thl and Th2 lymphocytic 'phenotypes in favour of the latter, which is influenced by genetic and environmental factors. This leads to the production of higher amounts, compared to non-allergic subjects, of cytokines (such as IL-4 and IL-5) contributing to allergic inflammation (6) . These cytokines are also accountable for the activation of eosinophils and for the isotypic switch from IgG to IgE production. Moreover, it is now clear that some T cell subsets have a regulatory function, hence leading to call them T regulatory, i.e. Treg, which is of paramount importance in the development of allergic diseases.
Two main types of Treg have been described, the innate Treg, which suppresses the response against self antigens, and the adaptive Treg, which ' influences and modulates the response to exogenous agents, including allergens (7) . On the basis of their surface phenotype, Tregs can be divided into Th3, Trl, CD4+CD25+, CD8+CD25+CD28-, Qadependent-CD8+, CD4-CD8-Treg and TCRgd-Treg, even though the fine functional differences among them are not yet fully characterized. CD4+CD25+ Tregs seem to control the functional activity ofThl and Th2 cells through the synthesis of IL-IO and/or TGF-beta (8) . IL-I0 is able to actively suppress allergen-specific T cell clones, to reduce the number of resident mast cells and their production of inflammatory cytokines, to reduce the activation and survival of eosinophils, and to increase the synthesis of IgG4 antibodies (8) . The production of the other isotype of protective antibodies -secretory IgA -is instead upregulated by TGF-beta (8) . It is evident that in normal subjects Tregs induce immune tolerance, which is abrogated in both autoimmune and allergic diseases. At the antibody level, the immune response of non-atopic subjects to allergens consists of protective IgG and IgA, while allergic subjects tend to produce IgE.
Effector cells sustaining allergic inflammation include mast cells, basophils and eosinophils. Mast cells are tissue-based inflammatory cells that respond to signals of innate and acquired immunity with both immediate and delayed release of inflammatory mediators (9) . In particular, their role in allergic diseases is related to their ability to be activated by the binding of the allergen to specific IgEs bound to the high affinity receptor FcepsilonRI. Such activation results in the release of preformed mediators contained in intracellular granules, as well as of newly synthesized lipid mediators from the membrane arachidonic acid, and cytokines (10) . The preformed mediators are responsible for the early phase of inflammation and include histamine, serine proteases, proteoglycans, and carboxypeptidase; histamine is the most studied of these mediators, and induces contraction of smooth muscles, vasodilation of blood vessels, mucus secretion, as well as endothelial cells and nerve endings stimulation. The role of proteases in inflammation is poorly known, in particular tryptase is able to elicit accumulation of inflammatory cells in vitro but its function in vivo is unclear, though it is commonly used (being produced only by mast cells) as a marker ofmast cell activation (II). Ofnote, it was recently suggested that proteases may control allergic inflammation through cleavage ofIgE molecules (12) .
Lipid mediators comprise products of the cycloxygenase cascade, such as prostaglandin 02 -a neutrophil chemoattractant -and oflipoxygenase cascade, such as leukotrienes LTC4, LT04 and LTE4, able to elicit potent bronchoconstriction and vasodilation. Regarding cytokines, mast cells release mostly TNF-alpha, involved in the upregulation of adhesion molecules and in bronchial responsiveness (13) , IL-3, IL-4, IL-5 (critical for IgE synthesis and eosinophil differentiation), IL-6, IL-8, IL-16, and GM-CSF, and also chemokines such as CCL3 which controls macrophage inflammation (14) .
Basophils are circulating granulocytes (representing less than 1% of blood leukocytes) which share with mast cells a number of features, particularly expression of the FcepsilonRI receptor and production of mediators and cytokines. They do not produce PG02 and IL-5, but are able to rapidly release IL-4 and IL-13, i.e. main cytokines involved in allergic inflammation (15). The expression of the chemokine receptors CCR2 and CCR3, implicated in inflammatory response to allergens is another clue to the participation of basophils to allergic inflammation.
Also eosinophils are circulating granulocytes (representing from 0.4 to 4% of blood leukocytes) which have distinctive characteristics. Their presence over the normal rate in blood, and especially in tissues, is a hallmark of allergy and asthma (9) . Eosinophils differentiate from bone-marrow precursors, proliferate under the influence of IL-5 (16) , and are recruited in the sites of inflammation by IL-4 and IL-13 as well as other chemotactic factors, such as leukotriene LTB4 and platelet activating factor (PAF). Their activation and survival is promoted by IL-3, IL-5, GM-CSF, CC chemokines, and PAF (17) . Eosinophils produce numerous inflammatory mediators, including cationic proteins contained in granules, with particular importance for the major basic protein (MBP), which correlates with bronchial hyperresponsiveness and asthma, as well as a number of cytokines such as IL-I, IL-3, IL-5, IL-8, TGF-beta, and TNF-alpha, and cysteinyl leukotrienes, particularly LTC-4. These properties imply a major role for eosinophils in sustaining prolonged allergic inflammation.
Immuno-competent cells, such as APC, T cells, macrophages, eosinophils and mast cells, secrete a number of cytokines and chemokines which ensure the regulation of activities such as growth, differentiation, activation, and survival of cells and tissues, the cytokine pattern being determinant in eliciting this kind of immune response (18) . These agents are produced de novo in response to a given immune stimulus and act by binding to cell membrane receptors, which transduce signals influencing cell behaviour. The name cytokines covers all such proteins, while distinctive names include lymphokines (produced by lymphocytes), monokines (produced by monocytes), chemokines (with chemotactic activities), and interleukins (produced by one leukocyte and acting on other leukocytes). The activity of cytokines is redundant, i.e different cytokines elicit similar functions, and their activity may be synergistic or antagonist. The number of identified cytokines is constantly growing, and their classification changes as a consequence of increasing knowledge.
Recently-identified cytokines closely associated with allergic inflammation include: IL-17, involved in eosinophil and neutrophil infiltration and in bronchial hyper-reactivity, which drives a subset of T cells with proinflammatory activity called TH 17 cells; IL-18, inducing IFN-gamma production from TH I cells but also, depending upon co-stimulatory factors, histamine release from basophils; IL-19, IL-20, IL-22, IL-24, and IL-26, belonging to the IL-lO family and possessing modulating activity, with a particular interest for IL-19, which has shown significantly higher levels in asthmatic patients compared to healthy subjects; IL-3l, involved in the recruitment ofmonocytes, polymorphonuclear cells, and T cells to sites of inflammation; IL-32, inducing proinflammatory cytokines and inflammatory proteins from macrophages (18) .
ANTI-INFLAMMATORY EFFECTS OF SUBLINGUAL IMMUNOTHERAPY
Allergen IT is the practice of administering gradually increasing doses of the specific allergen to reduce the clinical reactivity of allergic subjects, and it is the only treatment able to modify the natural course of allergy (2) . The two well-established forms ofSIT are subcutaneous immunotherapy (SCIT) -the traditional form for over a century -and sublingual immunotherapy (SLIT) -introduced as an alternative route to improve safety and adherence -which is now commonly used in Europe. Solid evidence obtained with SCIT from studies on mechanisms of action suggest that its ability to act on the natural course of allergy is strictly related to the effects on allergic inflammation (19) . Finally, the effects of SLIT turn out to decrease specific IgE antibodies as well as to increase allergen-specific IgG antibodies. The latter is associated with complex modifications of the pattern of cytokines and chemokines induced by the interaction between antigen presenting cells and T cells (Fig. 1) . Despite its much more recent introduction, literature on SLIT also consists of a bulk of data on its effectiveness in modifying the immune response to the administered allergen (20) .
Effects on antigen-presenting cells . Among antigen-presenting cells, DCs are significant inducers of tolerance to allergens through their interaction with T cells. The role ofDCs during SLIT seems of pivotal importance considering their activity in the immune response ofthe oral mucosa to allergens (21) . Oral tolerance has been evolutionary conserved to ensure immune tolerization to various antigenic stimuli from the environment, especially from food and commensal bacteria. During SLIT, as occurs in immunization at any mucosal surface, the allergen is captured locally by DCs by either phagocytosis, macropinocytosis orreceptor-mediated endocytosis. Following allergen capture, DCs mature and then migrate to proximal draining lymph nodes, as a consequence of changes in expression of surface receptors (e.g. the CCR7 chemokine receptor) involved in adhesion and trafficking (21) . The lymph nodes are specialized microenvironments favouring the induction of mucosal tolerance through the production of blocking IgG antibodies and the induction ofT lymphocytes with suppressive function (22) . Of note, the magnitude of CD4+ T cell responses elicited in lymph nodes is directly proportional to the number of allergen-carrying DCs that migrate to lymph nodes. As a consequence of the circulation of allergen-specific activated effector T cells and the persistence of memory cells, a local (i.e. sublingual) administration of the allergen results in a systemic and mucosal protective immune response. DCs from the oral mucosa constitutively express both low (CD23) and high (FCeRI) affinity receptors for IgEs, which favour IgE-mediated allergen capture in atopic individuals (4) . Following engagement of such IgE receptors, oral DCs produce ILIO, TGF-beta and up-regulate IDO (indole-amine 2 dioxygenase), a rate-limiting enzyme metabolizing tryptophan, thereby resulting in a decrease in T cell proliferation (4) . Further advances are provided by a recent study suggesting that toll like receptors (TLR), particularly TLR-4, induce an increased release of the anti-inflammatory cytokine IL-lO by oral DCs (23) .
Effects on T cells and cytokines
IT is the only approach able to redirect the immune response towards the Th 1 phenotype. This may occur by stimulation of a Thl-type response (immune deviation) related to an increased IFN-gamma and IL-2 production promoted and strengthened byvactivated macrophages and increased IL-12 synthesis, or by a Th2 reduced activity, through a mechanism of anergy or tolerance (24) . It has now been demonstrated that T cell tolerance is often associated with the generation of allergen-specific Treg cells (25) .
The milieu in which Treg cells, divided into Trl, Th3, and CD4+ CD25+ (the alpha chain of the IL-2 receptor, IL-2Ralpha), are generated and the mechanism through which they suppress the T-cell mediated immune response are not yet fully defined. However, the immunosuppressant and/or immunoregulatory contribution of IL-IO and TGFbeta cytokines seems essential to determine the effectiveness of IT (26) .
In particular, IL-! 0 -produced by Tr l, Th 1, Th2, mononuclear macrophages and NK cells -is involved in several steps of the allergic response, including: prolonged inhibition of the allergen-specific T CD4+ response; decrease in the number of resident mast cells and generation, recruitment and increased survival of eosinophils; reduction of the activation of allergen-specific Th2 cells and of the production of pro-inflammatory cytokines by macrophages and IgE-activated mast cells; decrease of IgE production and increase of IgG4 synthesis by B-Iymphocytes; suppression of the synthesis of cytokines produced by T-cells (such as IFN-gamma, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12, TNF-a1pha); synthesis of both CD23 and the adhesion molecule ICAM-1; reduction ofthe expression of co-stimulation signals between CD28 (present on T helper lymphocytes) and B7 (present on antigen presenting cells); inhibition of the APCmediated production of accessory signals for the activation ofT helper cells (27) .
The anergy of allergen-specific T cells observed after IT seems to partly depend upon the action of IL-10 (21). Of note, two studies on SCIT claimed a fundamental role in inducing such effect (28, 29) and similar observations were reported with SLIT (30) . In fact, in a study on SLIT with a birch pollen extract, a regulatory T-cell suppression through IL-10 during the early phase and immune deviation of allergen-specific T cells during the late phase of treatment were described, leading to conclusions that SLIT induces immune mechanisms comparable with Dendritic Cell /" SCIT (30) .
Another cytokine produced by Treg cells is TGFbeta, which seems to be produced after prolonged IT and is implicated in the modulation of the allergic reaction by suppressing allergen-specific T cells but also by stimulating the remodeling of tissues (31), being not yet known whether the balance between these two activities is beneficial or harmful. The cytokine most recently investigated in IT is IL-18, originally found as a factor inducing IFN-gamma production from Th1 cells (32) . In vitro studies have found that IL-18 in presence of1L-12 induces IFNgamma production and inhibits IgE synthesis and antigen-specific Th2 cell development, whereas in the absence of IL-12, IL-18 rather stimulate mast cells and basophils to produce IL-4 and IL-13, resulting in increased IgE synthesis (33) . Savolainen et al. reported that during high dose SLIT with a Betulacee pollen extract, IL-18 is upregulated along with the signaling lymphocytic activation molecule (SLAM), suggesting that the Th2 type inflammatory response is downregulated by SLIT by increased Th1 type response (33) . An additional recent observation APC: antigen presenting cell; IL: interleukin; IFN: interferon; TGF: transforming growth factor; NK: natural killer; CD: cluster ofdifferentiation; Th: T helper; Treg: T regulatory concerns the quick production of IFN-gamma, which was detected as soon as three months after the initiation of SLIT (34) .
Effects on antibody production
The first supposed mechanism of action of IT . was the induction of synthesis of allergen specific IgG antibodies acting as "blocking antibodies", because of their ability to prevent the interaction between the causative allergen and specific IgE and thus the release of mediators from mast cells and basophils (2) . Today, we know that the effects of IT on antibody synthesis depend upon the modifications of the pattern of cytokines and chemokines induced by the interaction between antigen-presenting cells and T cells (19) (20) . In early studies with SLIT, it seemed apparent that such a route of administration was unable to stimulate IgG synthesis, but in those studies low doses of allergen extracts were used. When appropriate dosing was used as suggested in consensus documents, i.e. at least 50-100 times higher than administered with SCIT (35) , an IgG response, mainly involving IgG4, was observed. A meta analysis of six SLIT studies with detailed assessment of antibody responses concluded to a consistent increase in allergen specific IgG4 levels (36) . A recent trial using three different maintenance doses reported a clear dose-dependence for IgG4 induction, since the highest serum levels, which were about 4 times the level measured in placebotreated patients, were detected in patients receiving the highest dose (37) . Concerning the IgA isotype, a phase 1111 trial with SLIT grass pollen tablets showed the induction of allergen-specific serum IgA in a dose-dependent fashion (38) , and an upregulation of IgA responses was also observed during SLIT in house dust mite allergic patients (39) . In addition to their blocking activity, allergen-specific IgG (and IgA) antibodies induced by IT are thought to contribute to the positive clinical outcome through a competition with IgE for allergen capture and presentation to T lymphocytes by FcepsilonRI+ and CD23+ antigen-presenting cells. They may also engage low affinity Fe receptors for immunoglobulins (e.g. FcgammaRII) expressed by B lymphocytes, basophils, or mast cells. Because FcgammayRII receptors contain immunoreceptor tyrosine-based inhibitory motifs (ITIM), they consequently transduce negative signals preventing cellular activation and release of soluble proinflammatory mediators following coaggregation with FCepsilonRI receptors (40) .
Effects on mast cells and eosinophils
The effects ofIT on mast cells and basophils were evaluated, similarly to antibody production, in studies conducted when the concept of immunoregulation by T cells and their cytokines was not yet defined. In these studies, it was apparent that the release of mediators induced by a nasal challenge with the specific allergen decreased significantly following IT and that such outcome preceded the detection of IgG antibodies (41) . Today, it is believed that the very early effects ofimmunotherapy, including SLIT, are related to mast cell and basophil desensitization, even ifa convincing explanation ofthis phenomenon is not yet available. Aspects which were elucidated include the modulation by IL-IO and IFN-gamma, once these cytokines are produced, of thresholds for mast cell and basophil mediator release (42) , as well as the decreased release of proinflammatory cytokines by mast cells induced by IL-IO through the inhibition of IL-6 (43) .
With regard to eosinophils, it is well known that IT decreases concomitantly the levels of their inflammatory protein ECP and bronchial hyperresponsiveness (44) . It also reduces chemotactic factors recruiting eosinophils, but also neutrophils, to the site of allergic inflammation. Moreover, eosinophils are the main player, with activated T cells, of the late-phase reaction elicited by exposure to the specific allergen, leading to the initial release by mast cells of products with chemotactic activity, that represents a clinical model of allergic inflammation. The capacity of IT to suppress the late-phase reaction is well known for SCIT (19) , and has recently been confirmed for SLIT (33) . It was demonstrated that SLIT prevents the recruitment of eosinophils in the eye or in the nose following allergen challenge, decreases local or systemic levels of eosinophil cationic protein (45) , and rapidly reduces (following a rush protocol) the recruitment of eosinophils -as well as neutrophils -into the nasal mucosa, along with the decreased expression of the ICAMI adhesion molecule (46) . It is of interest that, according to recent investigations by oral biopsies, inflammatory cells are present in very low numbers in the oral mucosa of subjects with local adverse reactions to SLIT and show negligible changes in biopsies obtained before and after the treatment (47) . In this study, the assessment of the oral mucosa was paralleled by an evaluation of the change in mast cells in the nose, measured by a nasal challenge, which demonstrated a significant reduction after treatment. This further confirms the tolerogenic property of the mouth and accounts for the well-known safety of SLIT (36) .
ROLE OF SUBLINGUAL IMMUNOTHERAPY IN TREATING ALLERGIC INFLAMMATION
Most patients with allergic inflammation in the upper and lower airway are currently treated with glucocorticosteroids, and in particular with topical preparations, which have high clinical efficacy while significantly reducing the side effects of oral or injective preparations (48) . Inhaled glucocorticosteroids are the mainstay in the treatment of persistent moderate to severe allergic asthma, which requires a maintenance therapy using controller drugs; also in allergic rhinitis topical steroids are the most effective treatment, especially when moderate to severe persistent symptoms occur (48) . The limit of glucocorticosteroids is that the effect on inflammation does not persist once they are discontinued, thus indefinite duration of treatment is needed. By contrast, allergen immunotherapy, including SLIT, is able to interfere with the natural course of respiratory allergy, since its anti-inflammatory effects are induced by the immunological changes related to the action on both regulatory and effector inflammatory cells (19, 24, 30) .
This ensures, provided immunotherapy is sufficiently protracted -at least 3-5 years according to consensus documents (2,35) -, a prolonged tolerance to the specific allergen after discontinuation.
